Immunization of Adult Zebrafish for the Preclinical Screening of DNA-based Vaccines.

J Vis Exp

BioMediTech Institute, Faculty of Medicine and Life Sciences, University of Tampere; Department of Pediatrics, Tampere University Hospital; Department of Children and Adolescents, Oulu University Hospital; PEDEGO Research Unit, Medical Research Center, University of Oulu;

Published: October 2018

The interest in DNA-based vaccination has increased during the past two decades. DNA vaccination is based on the cloning of a sequence of a selected antigen or a combination of antigens into a plasmid, which enables a tailor-made and safe design. The administration of DNA vaccines into host cells leads to the expression of antigens that stimulate both humoral and cell-mediated immune responses. This report describes a protocol for the cloning of antigen sequences into the pCMV-EGFP plasmid, the immunization of adult zebrafish with the vaccine candidates by intramuscular microinjection, and the subsequent electroporation to improve intake. The vaccine antigens are expressed as green fluorescent protein (GFP)-fusion proteins, which allows the confirmation of the antigen expression under UV light from live fish and the quantification of expression levels of the fusion protein with ELISA, as well as their detection with a western blot analysis. The protective effect of the vaccine candidates is tested by infecting the fish with Mycobacterium marinum five weeks postvaccination, followed by the quantification of the bacteria with qPCR four weeks later. Compared to mammalian preclinical screening models, this method provides a cost-effective method for the preliminary screening of novel DNA-based vaccine candidates against a mycobacterial infection. The method can be further applied to screening DNA-based vaccines against various bacterial and viral diseases.

Download full-text PDF

Source
http://dx.doi.org/10.3791/58453DOI Listing

Publication Analysis

Top Keywords

vaccine candidates
12
immunization adult
8
adult zebrafish
8
preclinical screening
8
screening dna-based
8
dna-based vaccines
8
zebrafish preclinical
4
screening
4
dna-based
4
vaccines interest
4

Similar Publications

Liver cancer is the sixth most frequent malignancy and the fourth major cause of deaths worldwide. The current treatments are only effective in early stages of cancer. To overcome the therapeutic challenges and exploration of immunotherapeutic options, broad spectral therapeutic vaccines could have significant impact.

View Article and Find Full Text PDF

Introduction: Vaccine platforms such as viral vectors and mRNA can accelerate vaccine development in response to newly emerging pathogens, as demonstrated during the COVID-19 pandemic. However, the differential effects of platform and antigen insert on vaccine immunogenicity remain incompletely understood. Innate immune responses induced by viral vector vaccines are suggested to have an adjuvant effect for subsequent adaptive immunity.

View Article and Find Full Text PDF

Psoralidin acts as a dual protease inhibitor against PL and M of SARS-CoV-2.

FEBS J

January 2025

Department of Life Sciences, School of Natural Sciences, Shiv Nadar Institution of Eminence, Gautam Buddha Nagar, Uttar Pradesh, India.

The emergence of new coronavirus variants and concerns about vaccine effectiveness against these novel variants emphasize the need for broad-spectrum therapeutics targeting conserved coronaviral non-structural proteins. Accordingly, a virtual library of 178 putative inhibitors targeting SARS-CoV-2 Papain-like protease (PL) was compiled through a systematic review of published literature and subsequently screened using molecular docking. Selected hits were analyzed for protease inhibitory activities, binding strength, and antiviral activities against HCoV229E-based surrogate system and subsequently against SARS-CoV-2 for validation.

View Article and Find Full Text PDF

Chain Length Does Matter: Development of High-Potency QS-21-Based Vaccine Adjuvants.

J Med Chem

January 2025

State Key Laboratory of Applied Organic Chemistry, Department of Chemistry, Lanzhou University, Lanzhou 730000, PR China.

Article Synopsis
  • Adjuvants like QS-21 are essential for boosting vaccine effectiveness, but QS-21 faces challenges such as limited availability, complex synthesis, and toxicity.
  • Researchers are working on creating simpler and safer analogues of QS-21 that maintain strong immunogenic properties.
  • The analogues VA05 and VA06 show promising results, generating similar antibody responses as QS-21 while being less toxic, making them potential candidates for better vaccine adjuvants.
View Article and Find Full Text PDF

Unlabelled: Porcine reproductive and respiratory syndrome (PRRS) remains a major threat to animal health and causes substantial economic losses worldwide. The nonstructural protein 11 (NSP11) of the causative agent, PRRS virus (PRRSV), contains a highly conserved nidoviral uridylate-specific endoribonuclease (NendoU) domain essential for viral replication and immune evasion. Targeting NSP11 offers a novel approach to antiviral intervention.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!